Showing 1 - 9 of 9
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Our data cover virtually all of the diseases borne by people in 52 countries during the period 1982-2001, and enable us to...
Persistent link: https://www.econbiz.de/10012468944
We develop a simple theoretical model of the allocation of public biomedical research expenditure, and present some empirical evidence about the determinants of this allocation. The structure of expenditure should depend on the relative costs as well as the relative benefits of different kinds...
Persistent link: https://www.econbiz.de/10012472210
Due in large part to intense takeover activity during the 1980s, the extent of American firms' industrial diversification declined significantly during the second half of the decade. The mean number of industries in which firms operated declined 14 percent, and the fraction of single-industry...
Persistent link: https://www.econbiz.de/10012475806
for estimation of the marginal productivity of workers classified by length of service to the firm, i.e., of the tenure …
Persistent link: https://www.econbiz.de/10012478450
There is a large body of work that documents a strong, positive correlation between education and measures of health, but little is known about the mechanisms by which education might affect health. One possibility is that more educated individuals are more likely to adopt new medical...
Persistent link: https://www.econbiz.de/10012469525
We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). We examine the effect of changes in both the average quantity and average vintage (FDA approval year) of drugs...
Persistent link: https://www.econbiz.de/10012469570
models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …
Persistent link: https://www.econbiz.de/10012469960
I examine the relationship across diseases between the long-run growth in the number of publications about a disease and the change in the age-adjusted mortality rate from the disease. The diseases analyzed are almost all the different forms of cancer, i.e. cancer at different sites in the body...
Persistent link: https://www.econbiz.de/10012459069
(active ingredients) in 20 OECD countries during the period 1995-2003 …
Persistent link: https://www.econbiz.de/10012464639